Mortality in South Africa is characterized by concurrent infectious and noncommunicable diseases. The 2015 mortality report confirms this transition, with tuberculosis (TB) and diabetes mellitus (DM) ranked the first and second leading causes of death, while human immunodeficiency virus type 1 (HIV-1) was ranked fifth \[[@CIT0001]\]. Although the role that HIV-1 plays as a significant driver of the TB epidemic is well recognized, the emerging and rapidly growing burden of DM, another TB risk factor, presents another challenge to TB control.

An increasing body of research shows an association between DM and TB \[[@CIT0002], [@CIT0003]\]. This association is becoming more apparent due to the epidemiological transition as DM is growing rapidly in settings where HIV-1 and TB epidemics persist. Diabetes increases the risk of developing TB and is also associated with adverse treatment outcomes, including death \[[@CIT0003]\].

Tuberculosis increases insulin resistance and stress-induced hyperglycemia that may revert to normal during treatment \[[@CIT0007], [@CIT0008]\]. Therefore, testing for DM in persons with recently diagnosed TB may lead to misclassification of transient hyperglycemia as DM, and overestimation of the diabetes/TB association. Testing for DM in TB patients is recommended, with confirmatory tests after 2--3 months of TB treatment initiation \[[@CIT0009], [@CIT0010]\]; however, the optimal time for screening and implications for clinical management are unknown.

The interplay between TB and DM in the context of HIV-1 infection remains unclear due to limited data particularly in the African context. A recent review that only included 3 African studies reported odd ratios (ORs) of TB in DM patients ranging from 0.9 (95% confidence interval \[CI\], .2--4.6) to 10.7 (95% CI, 4.5--26.0) \[[@CIT0011]\]. A previous study in Cape Town demonstrated significant TB and DM association in the group with HIV infection (OR, 2.4 \[95% CI, 1.1--5.2\]) vs HIV-uninfected patients (OR, 2.4 \[95% CI, .9--6.7\]) \[[@CIT0012]\]. A study in Tanzania observed a stronger TB/DM association among people living with HIV \[[@CIT0013]\], while another Tanzanian study observed stronger TB/DM association in HIV-1--uninfected persons (OR, 4.2 \[95% CI, 1.5--11.6\]) compared with people living with HIV (OR, 0.1 \[95% CI, .01--1.8\]) \[[@CIT0014]\]. These 3 diseases interact, with the potential to influence risk of disease and prognosis and to complicate clinical management \[[@CIT0015]\].

The objective of this study was to assess the association between hyperglycemia and TB, at TB diagnosis, and after 3 months of TB treatment.

METHODS {#s1}
=======

Study Setting and Population {#s2}
----------------------------

This study was conducted at the largest public-sector TB clinic in Khayelitsha, a periurban township of approximately 390  000 predominantly black Africans, in Cape Town, Western Cape province, where DM, HIV-1, and TB rank as the first, third, and fifth leading causes of death, respectively \[[@CIT0001]\]. The 2012 HIV-1 antenatal prevalence in Khayelitsha was 34% (95% CI, 31.0%--36.6%) (Western Cape Department of Health, Cape Town, South Africa; 2012 Antenatal Survey, unpublished data) and the 2015 TB case notification rate was 917 per 100  000 population (V. de Azevedo, City Health Manager, Cape Town; personal communication), with a 70% HIV-1/TB coinfection rate \[[@CIT0016]\]. The prevalence of diabetes is 13.1% (95% CI, 11.0%--15.1%) \[[@CIT0017]\].

Study Design and Sampling {#s3}
-------------------------

A 3-month cohort study on consecutive patients with respiratory symptoms presenting to the clinic from July 2013 to August 2015. Patients were eligible if they provided consent, were ≥18 years of age, and had received \<48 hours of TB chemotherapy. Those critically ill and in need of emergency clinical care were ineligible due to inability to provide informed consent. Based on the 4.5% and 1.2% prevalence of diabetes in TB patients and non-TB patients, respectively \[[@CIT0013]\], assuming 80% power and 5% significance level, the required sample size was 798 (n = 399 per group) \[[@CIT0018]\].

Study Procedures {#s4}
----------------

### Case Definitions {#s5}

All participants were tested for TB according to South African guidelines \[[@CIT0019]\]. Samples were analyzed in a centralized national health laboratory. TB cases had a positive GeneXpert result. Non-TB participants were those with a negative GeneXpert result, who after examination by a physician had resolution of respiratory symptoms without TB treatment after 3 months. HIV status and antiretroviral therapy (ART) were ascertained from participants\' medical records. For participants with unknown HIV status, voluntary HIV testing was offered, and if found to have HIV infection, they were provided counseling and ART initiation. All participants were tested for DM using fasting plasma glucose (FPG) and glycated hemoglobin (HbA1c). DM was defined as self-reported DM, FPG ≥7.0 mmol/L, or HbA1c ≥6.5%. Impaired glucose regulation (IGR) was defined as FPG 5.5 to \<7.0 mmol/L or HbA1c 5.7% to \<6.5% \[[@CIT0020]\].

### Measurements {#s6}

After TB diagnosis, sputum microscopy was repeated at months 3 and 5 in patients with pulmonary smear-positive TB according to South African guidelines \[[@CIT0019]\]. For DM diagnosis, venous blood was drawn after an overnight fast for FPG. At 3-month follow-up, both DM tests were repeated in all participants. All blood samples were processed on the day of collection at a centralized national health laboratory using standardized operating procedures of the Roche/Hitachi Cobas C311 system analyzer assay \[[@CIT0021]\]. Weight, height, and waist circumference were measured \[[@CIT0022]\]. The body mass index (BMI \[kg/m^2^\]) was categorized as follows: underweight, \<18.5; normal, 18.5--24.9; overweight, 25--29.9; obese, ≥30) \[[@CIT0022]\]. The cutoff point for high waist circumference was ≥94 cm (males) and ≥88 cm (females) \[[@CIT0022]\]. Hypertension was defined as a single measured blood pressure (BP) of systolic BP \>140 mm Hg or diastolic BP \>90 mm Hg \[[@CIT0020]\], or a preexisting diagnosis.

### Questionnaire {#s7}

Socioeconomic, demographic, and chronic medical and medication history for HIV-1, DM, and hypertension were collected using a researcher-administered questionnaire.

Statistical Analysis {#s8}
--------------------

Medians and interquartile ranges (IQRs) and proportions summarized continuous and categorical variables. The χ ^2^ and Fisher exact tests assessed associations between categorical variables, respectively. The Mann-Whitney test was used to compare medians between 2 groups and the Kruskal-Wallis test for \>2 groups. A multivariable logistic regression model for TB/DM association was manually built, using forward selection, controlling for potential confounding variables. To retain statistical power in the regression analysis, multiple imputation was used to impute HIV-1 serostatus for 50 participants with unknown HIV-1 status. We conducted sensitivity analysis comparing complete case and imputed analyses for multivariate analysis results on the association between TB and IGR/DM ([Supplementary Table 1](#sup1){ref-type="supplementary-material"}). Statistical significance was set at *P* \< .05. All data were analyzed using Stata version 13.0 software (StataCorp, College Station, Texas).

Ethical Considerations {#s9}
----------------------

This study was approved by the University of Cape Town Human Research Ethics Committee (HREC REF: 403/2011).

RESULTS {#s10}
=======

Study Sample at Enrollment {#s11}
--------------------------

Nine hundred eighty-six participants were recruited, and 48 participants (4.9%) were excluded as TB could not be confirmed or excluded. A further 88 participants did not complete diabetes screening at enrollment. For the analysis, 850 participants were included: 412 TB cases and 438 non-TB participants ([Figure 1](#F1){ref-type="fig"}).

![Participant recruitment flow diagram. Abbreviations: DM, diabetes mellitus; TB, tuberculosis.](ciz928f0001){#F1}

Participant Characteristics at Enrollment {#s12}
-----------------------------------------

Patient characteristics at enrollment have been previously described \[[@CIT0012]\]. The overall median age of participants was 38 (IQR, 31--47) years, with 53% male. Compared to those without TB, TB cases were younger, with a lower prevalence of central obesity, a greater proportion of men, and a higher proportion of previous incarceration ([Table 1](#T1){ref-type="table"}). Of the 412 TB cases, 9 had rifampicin resistance (2.2%) and did not have diabetes. The overall prevalence of HIV-1 infection was 61.1% (95% CI, 57.8%--64.4%); 67.2% (95% CI, 62.7%--71.8%) among TB cases; and 55.3% (95% CI, 50.1%--59.7%) among non-TB cases \[[@CIT0012]\].

###### 

Characteristics of Participants With and Without Tuberculosis at Enrollment

  Characteristic                                 Without TB (n = 438)   With TB (n = 412)   Total (N = 850)    *P* Value
  ---------------------------------------------- ---------------------- ------------------- ------------------ --------------
  Age, y                                                                                                       
   18--24                                        16 (3.7)               43 (10.4)           59 (6.9)           **\<.001**
   25--34                                        126 (28.8)             151 (36.7)          277 (32.6)         
   35--44                                        126 (28.8)             136 (33.0)          262 (30.8)         
   45--54                                        95 (21.7)              53 (12.9)           148 (17.4)         
   ≥55                                           75 (17.1)              29 (7.0)            104 (12.2)         
                                                                                            850                
  Age, y, median (IQR)                           41 (32--50)            36 (30--43)         38 (31--47)        **\<.001**
                                                                                            850                
  Sex                                                                                                          
   Female                                        224 (51.3)             175 (42.6)          399 (47.0)         **.011** ^a^
                                                                                            848                
  Education level                                                                                              
   Up to primary                                 130 (30.4)             129 (32.3)          259 (31.3)         .268
   Up to secondary                               289 (67.7)             257 (64.3)          456 (66.0)         
   Higher education                              8 (1.9)                14 (3.5)            22 (2.7)           
                                                                                            827                
  Marital status                                                                                               
   Single                                        276 (64.8)             299 (74.8)          575 (69.6)         **.002**
                                                                                            826                
  Work                                                                                                         
   Unemployed                                    235 (55.0)             213 (53.5)          448 (54.3)         .662
                                                                                            825                
  Household size                                                                                               
   0--2 individuals                              214 (51.7)             230 (59.3)          444 (55.4)         **.031**
   \>2individuals                                200 (48.3)             158 (40.7)          358 (44.6)         
                                                                                            802                
  Income, Rands, median (IQR)                    1295 (600--2970)       1900 (750--3000)    1200 (500--2000)   **\<.001**
  Binge drinking                                                                            698                
   Yes                                           425 (97.0)             403 (97.3)          828 (97.8)         .784
                                                                                            850                
  Current smoker                                                                                               
   Yes                                           123 (28.7)             90 (22.5)           213 (25.7)         **.04**
                                                                                            828                
  Prison history                                                                                               
   Yes                                           21 (4.9)               42 (10.3)           63 (7.5)           **.003**
                                                                                            837                
  Miner (past or present)                                                                                      
   Yes                                           17 (4.0)               7 (1.7)             24 (2.9)           .053
                                                                                            833                
  Healthcare worker                                                                                            
   Yes                                           8 (1.9)                7 (1.7)             15 (1.8)           .889
                                                                                            838                
  TB contact                                                                                                   
   Yes                                           54 (12.6)              51 (12.6)           105 (12.6)         .999
                                                                                            836                
  Previous TB                                                                                                  
   Yes                                           196 (46.0)             129 (31.9)          325 (39.2)         **\<.001**
                                                                                            830                
  Previous DM                                                                                                  
   Yes                                           19 (4.4)               20 (4.9)            39 (4.7)           .717
                                                                                            838                
  HIV-1 status                                                                                                 
   Uninfected                                    160 (36.5)             121 (29.4)          281 (33.1)         
   Infected                                      242 (55.3)             277 (67.2)          519 (61.1)         
   Unknown                                       36 (8.2)               14 (3.4)            50 (5.9)           
   Total                                         438                    412                 850                
                                                                                            850                
  ART status, among those with HIV-1 infection                                                                 
   Yes                                           166 (68.6)             89 (31.9)           255 (48.9)         **\<.001**
                                                                                            521                
  Hypertension                                                                                                 
   Yes                                           154 (35.2)             75 (18.1)           229 (26.9)         **\<.001**
                                                                                            850                
  BMI                                                                                                          
   \<18 kg/m^2^ (underweight)                    27 (6.6)               41 (10.3)           68 (8.4)           **\<.001**
   18--25 kg/m^2^ (normal)                       224 (54.4)             277 (69.6)          501 (61.9)         
   26--30 kg/m^2^ (overweight)                   69 (16.8)              59 (14.8)           128 (15.8)         
   \>30 kg/m^2^ (obese)                          92 (22.3)              21 (5.3)            113 (14.0)         
                                                                                            810                
  Waist circumference                                                                                          
   Raised (\>94 cm males; \>88 cm females)       144 (28.9)             53 (14.3)           167 (21.8)         **\<.001**
                                                                                            765                

Data are presented as no. (%) unless otherwise indicated. Number of participants is shown at the end of each category. Values in bold indicate statistical significance.

Abbreviations: ART, antiretroviral therapy; BMI, body mass index; HIV-1, human immunodeficiency virus type 1; IQR, interquartile range; TB, tuberculosis.

Study Sample at Follow-up {#s13}
-------------------------

Of the 850 patients enrolled, 639 returned for 3-month follow-up with 211 patients lost to follow-up (108 TB,103 non-TB) ([Figure 1](#F1){ref-type="fig"}). Data comparing participants lost to follow-up to those followed up are presented in [Supplementary Table 2.](#sup1){ref-type="supplementary-material"}

Glycemic Levels in TB Patients at Enrollment and Follow-up {#s14}
----------------------------------------------------------

Among TB patients with newly diagnosed DM, median HbA1c decreased at follow-up (5.7% vs 5.4%; *P* \< .0001), although FPG in this group slightly increased (4.6 vs 4.7 mmol/L; *P* \< .0064) at follow-up ([Table 2](#T2){ref-type="table"}). Among those with a preexisting diagnosis of DM, glycemic levels were sustained at high levels with no significant changes at follow-up ([Table 2](#T2){ref-type="table"}).

###### 

Glycemic Levels Among Participants With Tuberculosis

                                             Enrollment (n = 412)   Follow-up (n = 304)                                                   
  ------------------------------------------ ---------------------- --------------------- ------------------ -------- ------------------- ------------------
  IGR                                                                                                                                     
   HbA1c                                     147/363                40.7 (36.1--45.6)      6.0 (5.9--6.2)    39/276   12.8 (9.7--17.5)     5.9 (5.8--6.0)
   FPG                                       40/363                 10.9 (8.3--14.4)       5.8 (5.7--6.3)    29/276   10.5 (7.5--14.5)     5.3 (4.8--5.7)
   HbA1c or FPG                              177/363                48 (42.2--51.8)        ...               62/276   21.8 (16.9--26.3)    ...
  Newly diagnosed DM and preexisting DM^a^                                                                                                
   HbA1c                                     42/410                 10.2 (7.6--13.6)      7.6 (6.6--11.7)    16/296   5.4 (3.3--8.6)      10.3 (7.3--11.3)
   FPG                                       18/410                 4.4 (.3--6.9)         8.9 (7.8--12.0)    13/296   4.4 (2.6--7.5)      10.6 (7.2--15.4)
   HbA1c or FPG                              48/410                 11.9 (9.10--15.4)     ...                22/296   9.3 (6.4--13.0)     ...
  Newly diagnosed DM only                                                                                                                  
   HbA1c                                     25/390                 6.4 (4.2--9.2)        6.7 (6.5--7)       6/284    2.1 (1.0--4.7)      6.6 (6.6--10.8)
   FPG                                       9/390                  2.3 (1.2--4.4)        8.7 (8.1--8.9)     4/284    1.4 (.5--3.7)       10.3 (7.1--14.5)
   DM defined by HbA1c or FPG                28/390                 7.1 (5.1--10.4)        ...               9/284    2.9 (1.4--5.7)       ...
  Preexisting DM only                                                                                                                      
   HbA1c                                     18/20                  89.5 (62.9--97.7)     11.2 (7.9--12.9)   10/14    71.4 (39.9--90.4)   9.3 (5.7--11.2)
   FPG                                       9/20                   45 (25.0--70.8)       6.9 (4.8--10.1)    9/14     64.3 (39.9--90.4)   8.7 (6.4--15.4)
   HbA1c or FPG                              20/20                  100.00                 ...               14/14    100.00               ...

Abbreviations: CI, confidence interval; DM, diabetes mellitus; FPG, fasting plasma glucose; HbA1c, glycated hemoglobin; IGR, impaired glucose regulation; IQR, interquartile range; TB, tuberculosis.

^a^Differences in denominator (n = 2 at enrollment and n = 8 at follow-up) due to exclusion of participants with missing DM diagnostic tests for either test.

Prevalence of Diabetes and Impaired Glucose Regulation Among Patients With TB at Enrollment and Follow-up {#s15}
---------------------------------------------------------------------------------------------------------

The overall (including newly diagnosed DM and preexisting DM) prevalence of DM based on either HbA1c or FPG diagnostic tests was 11.9% (95% CI, 9.1%--15.4%) at enrollment and 9.3% (95% CI, 6.4%--13%) at follow-up (*P* = .273). The prevalence of IGR was 46.9% (95% CI, 42.15%--51.8%) and 21.5% (95% CI, 16.9%--26.3%) at follow-up (*P* \< .001; [Table 2](#T2){ref-type="table"}). Among those with preexisting DM, glycemic levels were high ([Table 2](#T2){ref-type="table"}) beyond the cutoff for DM diagnosis at both enrollment and follow-up ([Table 2](#T2){ref-type="table"}).

Glycemic Profile Among TB Patients {#s16}
----------------------------------

At enrollment, using both combined tests, 58.9% (n = 243) of TB patients were hyperglycemic (DM and IGR). This prevalence decreased to 30.8% (n = 94) at follow-up ([Figure 2](#F2){ref-type="fig"}); 2.6% (n = 10) with DM at enrollment reverted to normal at follow-up; and 22.5% (n = 105) of patients with IGR reverted to normal at follow-up ([Figure 2](#F2){ref-type="fig"}). With respect to diagnostic test, hyperglycemia detected by HbA1c was 51.2% (n = 186) enrollment and 18.5% (n = 65) at follow-up; and hyperglycemia detected by FPG was 15.4% (n = 38) at enrollment and 14.9% (n = 37) at follow-up.

![Changes in the prevalence (%) of hyperglycemia (IGR and DM) among patients with tuberculosis (TB) at enrollment (when TB diagnosed) and follow-up (3 months later). Abbreviations: DM, diabetes mellitus; FPG, fasting plasma glucose; HbA1c, glycated hemoglobin; IGR, impaired glucose regulation.](ciz928f0002){#F2}

Association Between Hyperglycemia (DM and IGR) and TB at Enrollment and Follow-up {#s17}
---------------------------------------------------------------------------------

Irrespective of HIV-1 status, the overall TB/DM association was positive and significant at both enrollment (OR, 2.4 \[95% CI, 1.3--4.3\]) and at follow-up (OR, 3.3 \[95% CI, 1.5--7.3\]) but only when DM was defined by a positive result for either of the diagnostic tests or a previous DM history ([Table 3](#T3){ref-type="table"}). This significant association was not observed at either time point when DM diagnostic tests were used in isolation ([Table 3](#T3){ref-type="table"}).

###### 

Association Between Tuberculosis and Diabetes Mellitus or Impaired Glucose Regulation at Enrollment and 3-Month Follow-up

                                                    Enrollment           Follow-up                                                                              
  ------------------------------------------------- -------------------- --------------------- -------------------- --------------------- --------------------- ---------------------
  IGR                                                                                                                                                           
   No IGR                                           1.0                  1.0                   1.0                  1.0                   1.0                   1.0
   IGR by HbA1c                                     **1.6 (1.1--2.3)**   1.5 (1.0--2.3)        **2.2 (1.2--4.1)**   0.6 (.4--1.1)         0.6 (.3--1.2)         0.8 (.3--2.0)
   IGR by FPG                                       0.9 (.5--1.5)        1.2 (.6--2.2)         0.4 (.1--1.2)        1.2 (.6--2.3)         0.8 (.3--2.2)         1.6 (.6--4.2)
   IGR by combined test (HbA1c or FPG)              **2.3 (1.6--3.3)**   **2.4 (1.51--3.8)**   **2.3 (1.1--4.7)**   0.84 (.53--1.36)      0.77 (.41--1.16)      1.10 (.47--2.57)
  Combining preexisting DM and newly diagnosed DM                                                                                                               
   No DM                                            1.0                  1.0                   1.0                  1.0                   1.0                   1.0
   DM by HbA1c                                      **2.4 (1.2--4.6)**   2.4 (1.0--5.9)        2.2 (.7--6.3)        2.1 (.8--5.3)         2.5 (.5--11.8)        1.8 (.5--6.7)
   DM by FPG                                        2.3 (1.0--5.9)       2.9 (.7--12.2)        1.9 (.7--6.4)        2.8 (.9--8.4)         9.8 (.9--106.6)       1.6 (.4--6.5)
   DM by combined test (HbA1c or FPG)               **2.8 (1.5--5.3)**   **2.4 (1.0--5.3)**    **3.5 (1.2--9.8)**   **3.3 (1.5--7.3)**    **3.8 (1.2--12.3)**   **3.5 (1.1--11.0)**
  Newly diagnosed DM only                                                                                                                                       
   No DM                                            1.0                  1.0                   1.0                  1.0                   1.0                   1.0
   DM by HbA1c                                      1.6 (.7--3.6)        1.7 (1.0--2.9)        1.0 (.1--7.6)        1.5 (.3--7.0)         1.3 (.2--8.1)         2.4 (.1--49.1)
   DM by FPG                                        1.7 (.3--8.8)        9.2 (.9--97.0)        2.2 (1.0--4.7)       3.0 (.2--40.5)        ^a^                   2.0 (.6--7.2)
   DM by combined test (HbA1c or FPG)               2.2 (1.0--4.7)       1.6 (.7--4.0)         3.6 (.7--19.5)       2.0 (.6--7.2)         1.6 (.3--7.3)         4.5 (.3--59.9)
  Preexisting DM only                                                                                                                                           
   No DM                                            1.0                  1.0                   1.0                  1.0                   1.0                   1.0
   DM                                               **3.7 (1.5--9.1)**   **6.3 (1.3--30.8)**   3.1 (.9--10.1)       **4.0 (1.6--10.1)**   **9.3 (1.7--49.0)**   3.0 (.9--10.1)

Data are presented as odds ratio (95% confidence interval). Bold text represents significant associations. Reference group for the associations: patients with no DM or IGR. All odds ratios were adjusted for sex, age, household size, income, hypertension (baseline), previous miner, previous prisoner, marital status, work status, and HIV-1 status.

Abbreviations: DM, diabetes mellitus; FPG, fasting plasma glucose; HbA1c, glycated hemoglobin; HIV, human immunodeficiency virus; IGR, impaired glucose regulation.

^a^Insufficient data to perform test-specific analysis.

The overall association between TB and IGR (by FPG or HbA1c) was positive at enrollment (OR, 2.3 \[95% CI, 1.6--3.3\]; [Table 3](#T3){ref-type="table"}) but not at follow-up (OR, 0.8 \[95% CI, .5--1.4\]). On further analysis by DM diagnostic test, the overall TB/IGR association at enrollment was significant when using the HbA1c test (OR, 1.6 \[95% CI, 1.1--2.3\]) but not by FPG (OR, 0.9 \[95% CI, .5--1.5\]) ([Table 3](#T3){ref-type="table"}).

Comparison of the Association Between TB/Newly Diagnosed DM and TB/Preexisting DM {#s18}
---------------------------------------------------------------------------------

At enrollment, 4.5% (95% CI, 2.8%--6.8%; n = 20) of patients had preexisting DM. All these patients had poorly controlled DM as evidenced by high glycemic levels at enrollment and follow-up ([Table 2](#T2){ref-type="table"}). On restricting analysis to patients with newly diagnosed DM, the TB/DM association was significant at enrollment (OR, 2.12 \[95% CI, 1.0--4.7\]) but not at follow-up ([Table 3](#T3){ref-type="table"}). By contrast, the association between TB and preexisting DM was significant at both enrollment (OR, 3.7 \[95% CI, 1.5--9.1\]) and follow-up (OR, 4.0 \[95% CI, 1.6--10.1\]) ([Table 3](#T3){ref-type="table"}).

DISCUSSION {#s19}
==========

We previously reported the prevalence of DM in patients with newly diagnosed TB and the cross-sectional TB/DM association at enrollment \[[@CIT0012]\]. In this study, we investigated whether hyperglycemia identified in the patients with newly diagnosed TB at enrollment persisted after 3 months of TB treatment. We also assessed association between TB and hyperglycemia at both time points. This is the first study in South Africa, a setting of high TB and DM burden, to document transient hyperglycemia in TB patients with preexisting DM and newly diagnosed DM. Overall, we report significant association between TB and DM at both enrollment and follow-up and significant association between TB and IGR at enrollment but not follow-up. However, when these results were further analyzed by DM category (newly diagnosed vs preexisting) and by HIV status within these categories, differing patterns emerged. Given the socioeconomic conditions of our study setting, the patients with newly diagnosed DM in our study may represent the proportion of undiagnosed DM due to factors associated with limited access to DM screening and having health facilities overwhelmed by TB and HIV \[[@CIT0017]\].

Newly Diagnosed DM {#s20}
------------------

Hyperglycemia, transient in the majority of participants with newly diagnosed DM and IGR, was predominantly accounted for by the latter at enrollment, and normalized at follow-up. Similar to our findings, other studies have shown frequent hyperglycemia in patients with TB at initiation of TB treatment, followed by normalization during treatment \[[@CIT0023]\]. This may be due to inflammation in response to active TB \[[@CIT0025]\], driven by complex interactions between hormones and cytokines \[[@CIT0024]\].

Consistent with the literature, the association between DM/IGR and TB in newly diagnosed DM participants was only significant at enrollment but not at follow-up. With respect to the different diagnostic tests separately, none of the associations were significant.

Preexisting DM {#s21}
--------------

Patients with preexisting DM had poorly controlled disease at both diagnosis of TB and 3 months later, as reflected by both FPG and HbA1c at these timepoints. Unlike newly diagnosed DM participants, the significant TB/DM association at enrollment (OR, 3.7 \[95% CI, 1.5--9.1\]) in this group, which persisted at follow-up (OR, 4.0 \[95% CI, 1.6--10.1\]), reflects poor glycemic control between the study timepoints. Hyperglycemia may have been exacerbated by acute TB. The persistence of raised glycemic levels reflects inadequate management of these patients, possibly due to poor follow-up, and highlights the complexity of clinical care in this subgroup.

A Korean retrospective study showed that TB is usually diagnosed 1 year following the diagnosis of DM \[[@CIT0027]\]. Therefore, the observed relative odds of preexisting DM among patients with TB compared to those without TB in this study (OR, 2.8 \[95% CI, 1.5--5.3\]) may approximate the relative risk to develop TB among patients with diabetes. Although the temporal relationship between TB and DM remains contentious, irrespective of the causal direction, comorbidity of TB and DM increases the risk of adverse TB treatment outcomes including treatment failure, mortality, and drug resistance \[[@CIT0003], [@CIT0005], [@CIT0013]\]. The observed poorly managed DM in these individuals with TB also highlights the increased risk of adverse TB treatment outcomes among these patients.

TB, DM, and HIV {#s22}
---------------

When stratified by HIV-1 status, the TB/DM association (when DM is defined by the different diagnostic tests separately) was not significant at either time point. Interaction between HIV, TB and DM is still not well understood and different studies report varying results.

It is complicated to interpret the interplay between TB, HIV, and DM as a wide range of factors may influence what is observed. This includes the effect of ART, HIV-1 infection as an independent risk factor for both DM and TB, or the choice of diagnostic test. Cotrimoxazole, administered to people living with HIV-1, can lead to hypoglycemia \[[@CIT0028]\]. Conversely, ART, particularly regimens containing protease inhibitors, increases insulin resistance, thus increasing the risk of diabetes \[[@CIT0029]\].

Other studies suggest that HbA1c may underestimate the presence of hyperglycemia in people living with HIV-1 and that this may be due to nucleoside reverse transcriptase inhibitor use \[[@CIT0030], [@CIT0031]\]. In our study, HbA1c detected a higher prevalence of hyperglycemia. In a 2015 review by English et al, it was suggested that an HbA1c test is likely to be affected by iron deficiency anemia and may result in spurious increases of HbA1c level \[[@CIT0032]\]. On the other hand, non--iron deficiency anemia may lead to a reduction in HbA1c levels \[[@CIT0032], [@CIT0033]\]. A recent study observed lower HbA1c mean levels in severely anemic patients; however, due to a limited sample, no further analysis was performed to explore this relationship \[[@CIT0034]\]. The effect of anemia on the direction of the association is therefore unclear.

We explored the potential effect of unmeasured confounding on our results by performing sensitivity analysis ([Supplementary Table 3](#sup1){ref-type="supplementary-material"}) \[[@CIT0035]\]. This showed that in IGR and newly diagnosed DM, the association with TB was rendered nonsignificant at baseline and follow-up. As such we note that weaker residual confounding may explain away our observed estimates. However, the association between TB and preexisting DM was significant both at enrollment and follow-up with ORs ranging between 3.7 and 9.3. To explain away these associations, an unmeasured confounder would need to be associated with both TB and preexisting DM with risk ratios ranging between 2.9 and 6.9, but weaker confounding would not.

There were strengths and limitations to this study. A limited number of studies have evaluated hyperglycemia in individuals with TB, particularly in Africa where there is a high prevalence of comorbidity with other diseases such as HIV-1. TB cases were diagnosed according to South African guidelines \[[@CIT0019]\], with the Gene Xpert analyzed in a centralized national health laboratory. For enrollment and follow-up, DM measurements were performed using 2 recommended tests. We relied on medical records to document ART use, as such we could not reliably ascertain duration of ART use in our multivariate analysis.

Our study follow-up time was limited to 3 months and we were not able to analyze the effect of hyperglycemia on TB outcomes. Because critically ill patients were excluded in the study, it may have biased the study population to appear healthier.

The proportion of participants lost to follow-up in this study, and to the health system, was relatively high (n = 212 \[24.9%\]) ([Supplementary Table 2](#sup1){ref-type="supplementary-material"}). Those followed up were older, mostly unemployed, and likely to have known DM and hypertension. Our results at follow-up may thus be slightly biased as they represent an older population prone to chronic conditions. Reasons for loss to follow-up include migration to other parts of the country and transfer to other health facilities in the province. To reduce bias and loss of statistical power, we imputed HIV status for patients with unknown HIV status. Therefore, loss to follow-up is less likely to have biased the associations observed in the study. The loss to follow-up observed in this study reflects how patients are lost in healthcare systems in this setting. This therefore highlights the importance of improving retention of patients in care for optimal management of all chronic diseases.

CONCLUSIONS {#s23}
===========

This is the first study in the South African context of high TB/HIV and rapidly increasing DM burdens to describe changes in glucose levels among patients with TB during treatment. This study showed that hyperglycemia was common in TB patients with DM. This confirms the need for confirmation DM tests in TB patients during and/or after the course of TB treatment. The association between DM and TB persisted at follow-up in participants with preexisting DM, particularly those infected with HIV-1. This highlights an important need for improved co-management of TB, DM, and HIV to limit the risks of adverse outcomes.

Supplementary Data {#s24}
==================

Supplementary materials are available at *Clinical Infectious Diseases* online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

###### 

Click here for additional data file.
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